3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Sarcoma, Ewing
4
Ovarian Neoplasms
4
Uterine Neoplasms
2
Uterine Cervical Neoplasms
2
Sarcoma
2
Neoplasms
2
Melanoma
2
Carcinoma, Non-Small-Cell Lung
2
Rare Diseases
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neoplasms, Connective and Soft Tissue
1
Neoplasms, Connective Tissue
1
Neoplasms, Bone Tissue
1
Neoplasms by Histologic Type
1
Lung Neoplasms
1
Liver Neoplasms
1
Fallopian Tube Neoplasms
1
Carcinoma, Ovarian Epithelial
1
Interventions
Pemetrexed
5
ponatinib
4
pembrolizumab
4
Carboplatin
4
Cisplatin
3
130-nm albumin-bound paclitaxel
3
tetulomab tetraxetan lu-177
2
pralsetinib
2
osimertinib
2
napabucasin
2
fludarabine
2
ficlatuzumab
2
entinostat
2
durvalumab
2
atezolizumab
2
Rituximab
2
Paclitaxel
2
Lutetium
2
Irinotecan
2
Immunotherapy
2
Imatinib Mesylate
2
Gemcitabine
2
Doxorubicin
2
Dexamethasone
2
Cyclophosphamide
2
Bortezomib
2
Bevacizumab
2
vorasidenib
1
siltuximab
1
ruxolitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Neoplasms by Histologic Type
×
FANG vaccine
×
Clear all
NCT03495921
2023-04-26
VITA
Gradalis, Inc.
Phase 3
Terminated
32 enrolled
13 charts